ArticlePloS one2019
Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with improved outcomes after lung transplantation: A single centre experience.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- CD38-targeted therapy with Daratumumab in clinical lung transplantation: A single-center experience.JHLT open · 2025Article
- Changes in post-transplant serum testosterone levels in men undergoing lung transplantation: a pilot study using the TriNetX Research Network.International journal of impotence research · 2025Article
- [Immunological Aspects after Lung Transplantation].Zentralblatt fur Chirurgie · 2025Review
- Effect of chronic lung allograft dysfunction phenotypes on the outcome after lung retransplantation: A retrospective single-center data analysis.JTCVS open · 2025Article
- Serum proteomics analysis of lung transplant patients receiving different induction therapies.Frontiers in immunology · 2025Article
- Immunopathology of lung transplantation: from infection to rejection and vice versa.Frontiers in immunology · 2024Review
- Impact of Transient and Persistent Donor-Specific Antibodies in Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Current perspective of immunomodulators for lung transplant.Indian journal of thoracic and cardiovascular surgery · 2022Review
- Induction Therapy and Therapeutic Antibodies.Handbook of experimental pharmacology · 2022Article
- Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience.Frontiers in immunology · 2022Article
- Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibody detection in lung transplant recipients: A single-center experience.Immunity, inflammation and disease · 2021Article
- Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates.Yonsei medical journal · 2021Article
- Tacrolimus monitoring parameters are not associated with acute cellular rejection following lung transplantation.European journal of clinical pharmacology · 2021Article
- Developments in lung transplantation over the past decade.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Immunosuppressive strategies in lung transplantation.Annals of translational medicine · 2020Review
- Death after lung transplantation: improving long term survival despite perilous early postoperative years.Transplant international : official journal of the European Society for Organ Transplantation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
question addressed by the studyThe value of induction therapy in lung transplantation is controversial. According to the ISHLT, only about 50% of patients transplanted within the last 10 years received induction therapy. We reviewed our institutional experience to investigate the impact of induction therapy on short- and long-term outcomes. MATERIALS/PATIENTS AND
methodsBetween 2007 and 2015, 446 patients with a complete follow-up were included in this retrospective analysis. Analysis comprised long-term kidney function, infectious complications, incidence of rejection and overall survival.
resultsA total of 231 patients received alemtuzumab, 50 patients antithymocyte globulin (ATG) and 165 patients did not receive induction therapy (NI). The alemtuzumab group revealed the lowest rate of chronic kidney insufficiency (NI: 52.2%; ATG: 60%; alemtuzumab: 36.6%; p = 0.001). Both, the NI group (p<0.001) and the ATG group (p = 0.010) showed a significant increase of serum creatinine during follow-up compared to alemtuzumab patients. Furthermore, alemtuzumab group experienced the lowest rate of infection in the first year after transplantation. Finally, improved survival, low rates of acute cellular rejection (ACR), lymphocytic bronchiolitis (LB) and chronic lung allograft dysfunction (CLAD) were found in patients treated either with alemtuzumab or ATG.
conclusionAlemtuzumab induction therapy followed by reduced maintenance immunosuppression is associated with a better kidney function compared to no induction and ATG. Survival rate as well as freedom from ACR and CLAD were comparable between alemtuzumab and ATG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.